metoprolol has been researched along with Mitral Valve Insufficiency in 19 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Mitral Valve Insufficiency: Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mitral valve regurgitation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hemodynamic effects of the beta-receptor-blocking agent metoprolol (100 mg orally) and the calcium antagonist verapamil (160 mg orally) were analyzed in 24 patients with atrial fibrillation of different etiology (idiopathic atrial fibrillation, 6 cases; congestive cardiomyopathy, 6 cases; mitral stenosis, 5 cases; mitral regurgitation, 6 cases)." | 9.05 | [Modification of hemodynamics in tachycardiac atrial fibrillation by metoprolol and verapamil]. ( Bilgin, Y; Gigler, G; Maier, WD; Neuss, H; Schlepper, M; Thormann, J, 1983) |
| "Takotsubo syndrome, also called apical ballooning syndrome, is a clinical entity characterized by transient hypokinesis, akinesis, or dyskinesis of the left ventricular mid-segments with or without apical involvement, and without obstructive coronary lesions." | 5.36 | Haemodynamic effects of acute intravenous metoprolol in apical ballooning syndrome with dynamic left ventricular outflow tract obstruction. ( Bilato, C; Iliceto, S; Isabella, G; Migliore, F; Tarantini, G, 2010) |
| "Hemodynamic effects of the beta-receptor-blocking agent metoprolol (100 mg orally) and the calcium antagonist verapamil (160 mg orally) were analyzed in 24 patients with atrial fibrillation of different etiology (idiopathic atrial fibrillation, 6 cases; congestive cardiomyopathy, 6 cases; mitral stenosis, 5 cases; mitral regurgitation, 6 cases)." | 5.05 | [Modification of hemodynamics in tachycardiac atrial fibrillation by metoprolol and verapamil]. ( Bilgin, Y; Gigler, G; Maier, WD; Neuss, H; Schlepper, M; Thormann, J, 1983) |
| "Chronic mitral regurgitation (MR) is characterized by adverse ventricular remodeling and progressive LV dysfunction leading to heart failure (HF)." | 2.82 | Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. ( Garg, N; Goel, P; Kapoor, A; Khanna, R; Kumar, S; Sahoo, D; Sinha, A; Tewari, S, 2016) |
| "the effects of long-term administration of beta-blockers on left ventricular (LV) function during exercise in patients with ischemic heart disease (IHD) and idiopathic dilated cardiomyopathy (DCM) are controversial." | 2.71 | Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiop ( Andersson, B; Böhm, M; Darius, M; Delius, W; Goss, F; Osterziel, KJ; Sigmund, M; Strömblad, O; Trenkwalder, SP; Waagstein, F; Wahlqvist, I, 2003) |
| "Treatment with metoprolol prevented MR-associated oxidation of NO biosensor soluble guanylyl cyclase (sGC) within NLR." | 1.42 | Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy. ( Balligand, JL; Baskharoun, MM; Cannavo, A; Dell'Italia, LJ; Dillon, AR; Houser, SR; Jarrett, H; Koch, WJ; Liu, Y; McCormick, RC; Nanayakkara, G; Recchia, FA; Tillson, DM; Trappanese, DM; Tsai, EJ; Woitek, FJ, 2015) |
| "Early recognition of mitral valve prolapse in high-risk patients for severe mitral regurgitation or patients with underlying cardiovascular abnormalities such as an atrial septal defect is crucial to prevent morbid outcomes such as sudden cardiac death." | 1.42 | Emergent presentation of decompensated mitral valve prolapse and atrial septal defect. ( Das, B; Kang, J, 2015) |
| "Takotsubo syndrome, also called apical ballooning syndrome, is a clinical entity characterized by transient hypokinesis, akinesis, or dyskinesis of the left ventricular mid-segments with or without apical involvement, and without obstructive coronary lesions." | 1.36 | Haemodynamic effects of acute intravenous metoprolol in apical ballooning syndrome with dynamic left ventricular outflow tract obstruction. ( Bilato, C; Iliceto, S; Isabella, G; Migliore, F; Tarantini, G, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Dybro, AM | 1 |
| Rasmussen, TB | 1 |
| Nielsen, RR | 1 |
| Ladefoged, BT | 1 |
| Andersen, MJ | 1 |
| Jensen, MK | 1 |
| Poulsen, SH | 1 |
| Rabbani, M | 1 |
| Hafiz, A | 1 |
| Algadheeb, M | 1 |
| Thain, A | 1 |
| Kiaii, BB | 1 |
| Chuzi, S | 1 |
| Eucalitto, P | 1 |
| Yee, LM | 1 |
| Trappanese, DM | 1 |
| Liu, Y | 1 |
| McCormick, RC | 1 |
| Cannavo, A | 1 |
| Nanayakkara, G | 1 |
| Baskharoun, MM | 1 |
| Jarrett, H | 1 |
| Woitek, FJ | 1 |
| Tillson, DM | 1 |
| Dillon, AR | 3 |
| Recchia, FA | 1 |
| Balligand, JL | 1 |
| Houser, SR | 1 |
| Koch, WJ | 1 |
| Dell'Italia, LJ | 6 |
| Tsai, EJ | 1 |
| Kang, J | 1 |
| Das, B | 1 |
| Sahoo, D | 1 |
| Kapoor, A | 1 |
| Sinha, A | 1 |
| Khanna, R | 1 |
| Kumar, S | 1 |
| Garg, N | 1 |
| Tewari, S | 1 |
| Goel, P | 1 |
| Stewart, RA | 2 |
| Raffel, OC | 1 |
| Kerr, AJ | 1 |
| Gabriel, R | 1 |
| Zeng, I | 1 |
| Young, AA | 2 |
| Cowan, BR | 2 |
| Pat, B | 1 |
| Killingsworth, C | 1 |
| Denney, T | 2 |
| Zheng, J | 1 |
| Powell, P | 1 |
| Tillson, M | 1 |
| Migliore, F | 1 |
| Bilato, C | 1 |
| Isabella, G | 1 |
| Iliceto, S | 1 |
| Tarantini, G | 1 |
| Ennis, DB | 1 |
| Rudd-Barnard, GR | 1 |
| Li, B | 1 |
| Fonseca, CG | 1 |
| Carabello, BA | 1 |
| Ahmed, MI | 1 |
| Aban, I | 2 |
| Lloyd, SG | 1 |
| Gupta, H | 1 |
| Howard, G | 1 |
| Inusah, S | 1 |
| Peri, K | 1 |
| Robinson, J | 1 |
| Smith, P | 1 |
| McGiffin, DC | 1 |
| Schiros, CG | 1 |
| Alekseeva, IuM | 1 |
| Potievskaia, VI | 1 |
| Sakovich, EA | 1 |
| Sitnikov, AV | 1 |
| Soiustova, EL | 1 |
| Fin'ko, VA | 1 |
| Ardashev, AV | 1 |
| Tallaj, J | 2 |
| Wei, CC | 2 |
| Hankes, GH | 2 |
| Holland, M | 2 |
| Rynders, P | 2 |
| Ardell, JL | 2 |
| Armour, JA | 2 |
| Lucchesi, PA | 1 |
| Waagstein, F | 1 |
| Strömblad, O | 1 |
| Andersson, B | 1 |
| Böhm, M | 1 |
| Darius, M | 1 |
| Delius, W | 1 |
| Goss, F | 1 |
| Osterziel, KJ | 1 |
| Sigmund, M | 1 |
| Trenkwalder, SP | 1 |
| Wahlqvist, I | 1 |
| Dillon, R | 2 |
| Cardinal, R | 1 |
| Hoover, DB | 1 |
| Husain, A | 1 |
| Chockalingam, A | 1 |
| Tejwani, L | 1 |
| Aggarwal, K | 1 |
| Dellsperger, KC | 1 |
| Sabri, A | 1 |
| Rafiq, K | 1 |
| Seqqat, R | 1 |
| Kolpakov, MA | 1 |
| Maier, WD | 1 |
| Neuss, H | 1 |
| Bilgin, Y | 1 |
| Gigler, G | 1 |
| Thormann, J | 1 |
| Schlepper, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Metoprolol on Myocardial Function, Perfusion, Hemodynamics and Heart Failure Symptoms in Patients With Hypertrophic Obstructive Cardiomyopathy.[NCT03532802] | Phase 2 | 30 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)[NCT01052428] | Phase 2/Phase 3 | 38 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| The Study to Define the Unique Molecular Mechanisms of Mitral Regurgitation in Order to Find New Targeted Therapy to Attenuate the Remodeling and Delay the Need for Surgery and Improve Surgical Outcomes.[NCT01052532] | 65 participants (Actual) | Observational | 2005-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 62.62 | 63.90 | 63.80 | 41.90 | 61.70 | 44.70 | 60.95 | 53.79 | 59.95 |
| Toprol XL | 62.09 | NA | 61.29 | 54.81 | 62.77 | 68.47 | 62.05 | NA | 63.02 |
Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 91.66 | 90.93 | 90.84 | 70.56 | 88.99 | 82.73 | 90.16 | 85.75 | 87.31 |
| Toprol XL | 95.74 | NA | 95.24 | NA | 95.71 | 98.16 | 97.6 | NA | 95.16 |
Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 34.01 | 32.83 | 32.53 | 40.99 | 33.70 | 47.25 | 34.99 | 39.97 | 34.47 |
| Toprol XL | 35.98 | NA | 36.53 | NA | 35.89 | 30.97 | 36.72 | NA | 35.13 |
Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 0.61 | 0.53 | 0.62 | 0.67 | 0.65 | 0.65 | 0.65 | 0.61 | 0.64 |
| Toprol XL | 0.61 | NA | 0.6 | 0.53 | 0.60 | 0.55 | 0.59 | NA | 0.62 |
Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 4.76 | 5.02 | 4.51 | 4.15 | 4.46 | 4.61 | 4.43 | 4.72 | 4.52 |
| Toprol XL | 4.69 | NA | 4.85 | 5.74 | 4.79 | 5.02 | 4.77 | NA | 4.59 |
Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | EDV/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 2.27 | 2.58 | 2.38 | 1.56 | 2.26 | 1.83 | 1.95 | 1.73 | 2.17 |
| Toprol XL | 2.12 | NA | 2.08 | NA | 2.24 | 2.28 | 2.26 | NA | 2.25 |
Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent/%Systolic interval (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 87.94 | 115.07 | 45.90 | 37.2 | 87.85 | 52.95 | 88.11 | 67.53 | 79.94 |
| Toprol XL | 82.55 | NA | 78.68 | NA | 80.04 | 88.34 | 79.29 | NA | 85.18 |
1 review available for metoprolol and Mitral Valve Insufficiency
| Article | Year |
|---|---|
Dynamic left ventricular outflow tract obstruction in acute myocardial infarction with shock: cause, effect, and coincidence.
Topics: Adrenergic beta-Antagonists; Aged; Algorithms; Amiodarone; Cardiac Catheterization; Diagnosis, Diffe | 2007 |
7 trials available for metoprolol and Mitral Valve Insufficiency
| Article | Year |
|---|---|
Effects of Metoprolol on Exercise Hemodynamics in Patients With Obstructive Hypertrophic Cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Hemodynamics; Humans; Metoprolol; Mitral Valve Insufficiency; Stroke V | 2022 |
Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers.
Topics: Administration, Oral; Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Biomarkers; Chronic | 2016 |
Pilot study to assess the influence of beta-blockade on mitral regurgitant volume and left ventricular work in degenerative mitral valve disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Function, Left; Blood Pressure; Double-Blind Method | 2008 |
Changes in mitral annular geometry and dynamics with ß-blockade in patients with degenerative mitral valve disease.
Topics: Adrenergic beta-Antagonists; Cross-Over Studies; Double-Blind Method; Humans; Image Processing, Comp | 2010 |
A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Case-Control Studies; Female; Humans; Magnetic Resonance I | 2012 |
Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiop
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Double-Blind Method; Exercise; Exercise Test; | 2003 |
[Modification of hemodynamics in tachycardiac atrial fibrillation by metoprolol and verapamil].
Topics: Atrial Fibrillation; Cardiac Output; Cardiomyopathy, Dilated; Heart Rate; Hemodynamics; Humans; Meto | 1983 |
11 other studies available for metoprolol and Mitral Valve Insufficiency
| Article | Year |
|---|---|
A Case of Systolic Anterior Motion After Mitral Valve Repair Causing Hemolytic Anemia: Mechanism and Treatment.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anemia, Hemolytic; Echocardiography, Transesophageal; | 2020 |
A Pregnant Woman With Shortness of Breath.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anticoagulants; Cesarean Section; Dyspnea; Echocardio | 2021 |
Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Chronic Disease; Cyclic GMP; Dogs; Ethanolamines; G | 2015 |
Emergent presentation of decompensated mitral valve prolapse and atrial septal defect.
Topics: Abdominal Pain; Anticoagulants; Anxiety; Cardiotonic Agents; Continuous Positive Airway Pressure; Di | 2015 |
Dissociation between cardiomyocyte function and remodeling with beta-adrenergic receptor blockade in isolated canine mitral regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Anima | 2008 |
Haemodynamic effects of acute intravenous metoprolol in apical ballooning syndrome with dynamic left ventricular outflow tract obstruction.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Female; Heart Ventricles; Hemodynamics; Humans; Inject | 2010 |
Beta-blockade for mitral regurgitation: could the management of valvular heart disease actually be moving into the 21st century?
Topics: Adrenergic beta-Antagonists; Female; Humans; Male; Metoprolol; Mitral Valve Insufficiency | 2012 |
[The rare case of Bland-White-Garland syndrome in adult patient].
Topics: Adult; Benzazepines; Cardiovascular Agents; Cardiovascular Surgical Procedures; Coronary Angiography | 2012 |
Beta1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Catech | 2003 |
Beta1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Catech | 2003 |
Beta1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Catech | 2003 |
Beta1-adrenergic receptor blockade attenuates angiotensin II-mediated catecholamine release into the cardiac interstitium in mitral regurgitation.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Catech | 2003 |
Beta1-adrenoceptor blockade mitigates excessive norepinephrine release into cardiac interstitium in mitral regurgitation in dog.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Dogs; Extracellular Fl | 2006 |
Sympathetic activation causes focal adhesion signaling alteration in early compensated volume overload attributable to isolated mitral regurgitation in the dog.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Apoptosis; Cells, Cult | 2008 |